The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | Factors to predict PFS in patients with WM treated with BTK inhibitors: iNNOVATE & ASPEN
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, shares insights into studies evaluating the use of BTK inhibitors in Waldenström’s macroglobulinemia (WM), and further discusses factors that may be used to predict progression-free survival (PFS) in these patients. Referencing findings from the iNNOVATE and ASPEN studies (NCT02165397; NCT03053440), Dr Castillo explains that depth of response may not be the best factor to predict rates of PFS in patients treated with BTK inhibitors. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
